<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314662</url>
  </required_header>
  <id_info>
    <org_study_id>V118_20</org_study_id>
    <nct_id>NCT03314662</nct_id>
  </id_info>
  <brief_title>Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group,
      multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza
      vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2),
      containing the alternate B strain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial is designed as a double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.</measure>
    <time_frame>Day 22</time_frame>
    <description>The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis</measure>
    <time_frame>Day 22</time_frame>
    <description>The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer &gt;= 1:40 or a pre-vaccination HI titer &gt;= 1:10 and a &gt;= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.</measure>
    <time_frame>Day 22</time_frame>
    <description>The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.</measure>
    <time_frame>Day 22</time_frame>
    <description>The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains</measure>
    <time_frame>Day 1 and Day 22</time_frame>
    <description>For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains</measure>
    <time_frame>Day 22/Day 1</time_frame>
    <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains</measure>
    <time_frame>Day 1 and Day 22</time_frame>
    <description>The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains</measure>
    <time_frame>Day 22</time_frame>
    <description>The SCR was defined as the percentage of subjects with either a prevaccination HI titer &lt;1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Subjects With Unsolicited AEs</measure>
    <time_frame>Day 1 through Day 22</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)</measure>
    <time_frame>Day 1 through Day 181</time_frame>
    <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1778</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aTIV-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aTIV-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)</intervention_name>
    <description>The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
    <arm_group_label>aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)</intervention_name>
    <description>The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
    <arm_group_label>aTIV-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)</intervention_name>
    <description>The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
    <arm_group_label>aTIV-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 65 years old who are healthy or have co-morbidities

          -  Individuals who or whose legal representative(s) have voluntarily given written
             consent after the nature of the study has been explained according to local regulatory
             requirements, prior to study entry

          -  Ability to attend all scheduled visits and to comply with study procedures including
             diary card completion and follow-up

        Exclusion Criteria:

          -  History of behavioral or cognitive impairment or psychiatric condition

          -  Hypersensitivity, including allergy, to any component of vaccines, medicinal products
             or medical equipment whose use is foreseen in this study

          -  Abnormal function of the immune system

          -  Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or
             plan to receive influenza vaccine prior to the Day 22 blood collection

          -  Any other clinical condition that, in the opinion of the Investigator, might interfere
             with the results of the study or pose additional risk to the subject due to
             participation in the study

        Additional eligibility criteria may be discussed by contacting the site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Scientist</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm clinical Research Centers, Inc</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida, an AMR Company</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridan Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC - An AMR Company</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC - An AMR Company</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Diagnostic Clinic</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>March 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <disposition_first_submitted>November 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>November 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 26, 2018</disposition_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03314662/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03314662/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 study centers in the United States</recruitment_details>
      <pre_assignment_details>All enrolled subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aQIV</title>
          <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
        </group>
        <group group_id="P2">
          <title>aTIV-1</title>
          <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
        </group>
        <group group_id="P3">
          <title>aTIV-2</title>
          <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="889"/>
                <participants group_id="P2" count="445"/>
                <participants group_id="P3" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="888"/>
                <participants group_id="P2" count="444"/>
                <participants group_id="P3" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="881"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="439"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aQIV</title>
          <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
        </group>
        <group group_id="B2">
          <title>aTIV-1</title>
          <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
        </group>
        <group group_id="B3">
          <title>aTIV-2</title>
          <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="889"/>
            <count group_id="B2" value="445"/>
            <count group_id="B3" value="444"/>
            <count group_id="B4" value="1778"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.4" spread="5.54"/>
                    <measurement group_id="B2" value="72.4" spread="5.60"/>
                    <measurement group_id="B3" value="72.6" spread="5.46"/>
                    <measurement group_id="B4" value="72.5" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="517"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="1007"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="372"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="403"/>
                    <measurement group_id="B3" value="411"/>
                    <measurement group_id="B4" value="1628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="827"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="410"/>
                    <measurement group_id="B4" value="1645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="889"/>
                    <measurement group_id="B2" value="445"/>
                    <measurement group_id="B3" value="444"/>
                    <measurement group_id="B4" value="1778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>analysis presented for subjects with available data.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="885"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.54" spread="9.350"/>
                    <measurement group_id="B2" value="167.92" spread="10.535"/>
                    <measurement group_id="B3" value="168.38" spread="10.646"/>
                    <measurement group_id="B4" value="167.84" spread="9.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>analysis presented for subjects with available data.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="885"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.24" spread="19.064"/>
                    <measurement group_id="B2" value="84.18" spread="8.963"/>
                    <measurement group_id="B3" value="84.24" spread="17.825"/>
                    <measurement group_id="B4" value="83.73" spread="18.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>analysis presented for subjects with available data.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="885"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.60" spread="6.157"/>
                    <measurement group_id="B2" value="29.79" spread="5.858"/>
                    <measurement group_id="B3" value="29.69" spread="5.647"/>
                    <measurement group_id="B4" value="29.67" spread="5.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Vaccination History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="760"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="401"/>
                    <measurement group_id="B4" value="1541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Risk Score (Comorbidity)</title>
          <description>Comorbidity risk scores were assessed among other baseline characteristics and validated the risk of influenza complications in subjects ≥65 y.o. This model-based approach assessed 5 classifications: pulmonary disease, heart disease, renal disease, dementia or stroke, and non-hematological and hematological cancer [excl. cancer of the skin other than melanoma]).
The score(s) include: &lt;50 (low risk) to ≥50 (high risk for hospitalization due to pneumonia or influenza and death from any cause).
The outer ranges of the comorbidity scale (i.e., min and max) are below:
0 (min.) to 267 (max.)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="889"/>
                    <count group_id="B2" value="445"/>
                    <count group_id="B3" value="444"/>
                    <count group_id="B4" value="1778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="33.50"/>
                    <measurement group_id="B2" value="44.6" spread="30.25"/>
                    <measurement group_id="B3" value="46.5" spread="34.15"/>
                    <measurement group_id="B4" value="45.8" spread="32.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.</title>
        <description>The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.</description>
        <time_frame>Day 22</time_frame>
        <population>The per protocol set (PPS) Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the 2 influenza type B strains in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-2) contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
          <group group_id="O4">
            <title>aTIV-1/aTIV-2</title>
            <description>Pooled Subjects Treated with aTIV-1 and aTIV-2</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.</title>
          <description>The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.</description>
          <population>The per protocol set (PPS) Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results</population>
          <units>Geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.01" lower_limit="57.79" upper_limit="73.13"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="75.16" lower_limit="66.68" upper_limit="84.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.91" lower_limit="261.88" upper_limit="332.09"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="293.31" lower_limit="259.91" upper_limit="330.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.67" lower_limit="22.67" upper_limit="26.84"/>
                    <measurement group_id="O2" value="15.96" lower_limit="14.48" upper_limit="17.59"/>
                    <measurement group_id="O3" value="24.30" lower_limit="22.00" upper_limit="26.84"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.78" lower_limit="28.27" upper_limit="33.51"/>
                    <measurement group_id="O2" value="30.13" lower_limit="27.31" upper_limit="33.24"/>
                    <measurement group_id="O3" value="21.80" lower_limit="19.73" upper_limit="24.09"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV/aQIV - for strain A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% confidence interval (CI) for the ratios of GMTs (aTIV/aQIV) do not exceed 1.5</non_inferiority_desc>
            <param_type>GMT ratio (aTIV/aQIV)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV/aQIV - performed for strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% confidence interval (CI) for the ratios of GMTs (aTIV/aQIV) do not exceed 1.5</non_inferiority_desc>
            <param_type>GMT ratio: (aTIV/aQIV</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log 10 transformed), age, sex, vaccination history, study site</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aQIV/aTIV - performed for strain B/Yamagata</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% confidence interval (CI) for the ratios of GMTs (aTIV/aQIV) do not exceed 1.5.</non_inferiority_desc>
            <param_type>GMT ratio: aTIV/aQIV</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aQIV/aTIV - performed for strain B/Victoria</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% confidence interval (CI) for the ratios of GMTs (aTIV/aQIV) do not exceed 1.5.</non_inferiority_desc>
            <param_type>GMT ratio: (aTIV/aQIV)]</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis</title>
        <description>The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer &gt;= 1:40 or a pre-vaccination HI titer &gt;= 1:10 and a &gt;= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
        <time_frame>Day 22</time_frame>
        <population>The per protocol set (PPS) Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the 2 influenza type B strains in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-2) contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis</title>
          <description>The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer &gt;= 1:40 or a pre-vaccination HI titer &gt;= 1:10 and a &gt;= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
          <population>The per protocol set (PPS) Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="32" upper_limit="38.5"/>
                    <measurement group_id="O2" value="39.45" lower_limit="34.8" upper_limit="44.2"/>
                    <measurement group_id="O3" value="37.41" lower_limit="32.8" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.33" lower_limit="36.1" upper_limit="42.7"/>
                    <measurement group_id="O2" value="39.70" lower_limit="36.4" upper_limit="43.0"/>
                    <measurement group_id="O3" value="37.18" lower_limit="32.6" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.0" upper_limit="19.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not applicable as the strain is not present in aTIV vaccine</measurement>
                    <measurement group_id="O3" value="15.47" lower_limit="12.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" lower_limit="11.2" upper_limit="15.9"/>
                    <measurement group_id="O2" value="12.16" lower_limit="9.24" upper_limit="15.6"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not applicable as the strain is not present in aTIV vaccine</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV minus aQIV - for strain A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% CI for the differences between the SCRs (aTIV - aQIV) do not exceed 10% for each of the four strains</non_inferiority_desc>
            <param_type>SCR difference (aTIV minus aQIV)</param_type>
            <param_value>3.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>7.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV minus aQIV - for strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% CI for the differences between the SCRs (aTIV - aQIV) do not exceed 10% for each of the four strains</non_inferiority_desc>
            <param_type>SCR difference (aTIV minus aQIV)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.23</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV minus aQIV - for strain B-Yamagata</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% CI for the differences between the SCRs (aTIV - aQIV) do not exceed 10% for each of the four strains</non_inferiority_desc>
            <param_type>SCR difference (aTIV minus aQIV)]</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison Group Selection: aTIV minus aQIV - for strain B-Victoria</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>aQIV was considered non-inferior to aTIV-1 or aTIV-2 if the upper bound of the two-sided 95% CI for the differences between the SCRs (aTIV - aQIV) do not exceed 10% for each of the four strains</non_inferiority_desc>
            <param_type>Other [SCR difference (aTIV minus aQIV)]</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.07</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.</title>
        <description>The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.</description>
        <time_frame>Day 22</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the 2 influenza type B strains in the vaccine.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-2) contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.</title>
          <description>The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="32.03" upper_limit="38.48"/>
                    <measurement group_id="O2" value="39.45" lower_limit="34.80" upper_limit="44.20"/>
                    <measurement group_id="O3" value="37.41" lower_limit="32.8" upper_limit="40.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.33" lower_limit="36.08" upper_limit="42.67"/>
                    <measurement group_id="O2" value="39.70" lower_limit="36.43" upper_limit="43.04"/>
                    <measurement group_id="O3" value="37.18" lower_limit="32.6" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" lower_limit="14.0" upper_limit="19.03"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not applicable as the strain is not present in an aTIV vaccine</measurement>
                    <measurement group_id="O3" value="15.47" lower_limit="12.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" lower_limit="11.22" upper_limit="15.86"/>
                    <measurement group_id="O2" value="12.16" lower_limit="9.24" upper_limit="15.60"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not applicable as the strain is not present in an aTIV vaccine</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.</title>
        <description>The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.</description>
        <time_frame>Day 22</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the 2 influenza type B strains in the vaccine.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-2) contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine. The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.</title>
          <description>The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.38" lower_limit="66.20" upper_limit="72.43"/>
                    <measurement group_id="O2" value="71.79" lower_limit="67.31" upper_limit="75.97"/>
                    <measurement group_id="O3" value="68.82" lower_limit="64.23" upper_limit="73.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.92" lower_limit="92.12" upper_limit="95.41"/>
                    <measurement group_id="O2" value="94.72" lower_limit="92.19" upper_limit="96.63"/>
                    <measurement group_id="O3" value="94.92" lower_limit="92.41" upper_limit="96.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.80" lower_limit="29.69" upper_limit="36.03"/>
                    <measurement group_id="O2" value="21.79" lower_limit="18.00" upper_limit="25.96"/>
                    <measurement group_id="O3" value="36.95" lower_limit="32.39" upper_limit="41.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.19" lower_limit="34.95" upper_limit="41.51"/>
                    <measurement group_id="O2" value="36.93" lower_limit="32.38" upper_limit="41.65"/>
                    <measurement group_id="O3" value="24.48" lower_limit="20.50" upper_limit="28.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains</title>
        <description>For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.</description>
        <time_frame>Day 1 and Day 22</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
          <group group_id="O4">
            <title>aTIV-1/aTIV-2</title>
            <description>Pooled Subjects Treated with aTIV-1 and aTIV-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains</title>
          <description>For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.07" lower_limit="17.66" upper_limit="20.60"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="18.77" lower_limit="17.47" upper_limit="20.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.07" lower_limit="52.67" upper_limit="61.84"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="63.73" lower_limit="58.60" upper_limit="69.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.27" lower_limit="66.36" upper_limit="80.90"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="71.83" lower_limit="65.39" upper_limit="78.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.85" lower_limit="225.57" upper_limit="267.95"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="236.27" lower_limit="217.53" upper_limit="256.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.41" lower_limit="9.86" upper_limit="10.98"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="10.76" lower_limit="9.97" upper_limit="11.61"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.15" lower_limit="19.75" upper_limit="22.66"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="20.74" lower_limit="18.86" upper_limit="22.80"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.15" lower_limit="13.30" upper_limit="15.05"/>
                    <measurement group_id="O2" value="15.18" lower_limit="13.85" upper_limit="16.64"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.91" lower_limit="23.21" upper_limit="26.74"/>
                    <measurement group_id="O2" value="25.54" lower_limit="23.03" upper_limit="28.33"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Yamagata strain: GMT Ratio (aTIV/aQIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of aQIV vs. aTIV-1 for the alternate B strain was assessed using the GMT ratio (GMTaTIV/GMTaQIV); Superiority was declared if the upper limit of the two-sided 95% CI for the GMT ratio (aTIV/aQIV) was &lt;1. The superiority comparison was based on the Full Analysis Set (FAS) Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>B/Victoria Strain: GMT Ratio (aTIV/aQIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of aQIV vs. aTIV-2 for the alternate B strain was assessed using the GMT ratio (GMTaTIV/GMTaQIV); Superiority was declared if the upper limit of the two-sided 95% CI for the GMT ratio (aTIV/aQIV) was &lt;1. The superiority comparison was based on the FAS Immunogenicity.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains</title>
        <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.</description>
        <time_frame>Day 22/Day 1</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
          <group group_id="O4">
            <title>aTIV-1/aTIV-2</title>
            <description>Pooled Subjects Treated with aTIV-1 and aTIV-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains</title>
          <description>The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>geometric mean ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.78" upper_limit="3.22"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="3.40" lower_limit="3.14" upper_limit="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="3.07" upper_limit="3.66"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="3.29" lower_limit="3.02" upper_limit="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.92" upper_limit="2.15"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="1.93" lower_limit="1.79" upper_limit="2.08"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.66" upper_limit="1.86"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.55" upper_limit="1.82"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains</title>
        <description>The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
        <time_frame>Day 1 and Day 22</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
          <group group_id="O4">
            <title>aTIV-1/aTIV-2</title>
            <description>Pooled Subjects Treated with aTIV-1 and aTIV-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains</title>
          <description>The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.26" lower_limit="30.13" upper_limit="36.49"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="31.07" lower_limit="28.00" upper_limit="34.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.38" lower_limit="66.20" upper_limit="72.43"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="70.31" lower_limit="67.15" upper_limit="73.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.64" lower_limit="67.50" upper_limit="73.65"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="70.66" lower_limit="67.50" upper_limit="73.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.92" lower_limit="92.12" upper_limit="95.41"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="94.82" lower_limit="93.13" upper_limit="96.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.12" lower_limit="9.11" upper_limit="13.40"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="11.55" lower_limit="8.69" upper_limit="14.94"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.80" lower_limit="26.69" upper_limit="36.03"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="36.95" lower_limit="32.39" upper_limit="41.69"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.72" lower_limit="17.13" upper_limit="22.52"/>
                    <measurement group_id="O2" value="22.71" lower_limit="18.86" upper_limit="26.93"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.19" lower_limit="34.95" upper_limit="41.51"/>
                    <measurement group_id="O2" value="36.93" lower_limit="32.38" upper_limit="41.65"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains</title>
        <description>The SCR was defined as the percentage of subjects with either a prevaccination HI titer &lt;1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.</description>
        <time_frame>Day 22</time_frame>
        <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
          <group group_id="O4">
            <title>aTIV-1/aTIV-2</title>
            <description>Pooled Subjects Treated with aTIV-1 and aTIV-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains</title>
          <description>The SCR was defined as the percentage of subjects with either a prevaccination HI titer &lt;1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.
The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.</description>
          <population>The PPS Immunogenicity comprised all subjects who were randomized, received at least 1 study vaccination, and provided immunogenicity data at Day 1 and Day 22, and who did not have any major protocol deviations that were assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="32.03" upper_limit="38.48"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="38.43" lower_limit="35.19" upper_limit="41.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.33" lower_limit="36.08" upper_limit="42.67"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for individual strain.</measurement>
                    <measurement group_id="O4" value="39.70" lower_limit="36.43" upper_limit="43.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" lower_limit="14.00" upper_limit="19.03"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O3" value="15.47" lower_limit="12.20" upper_limit="19.23"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" lower_limit="11.22" upper_limit="15.86"/>
                    <measurement group_id="O2" value="12.16" lower_limit="9.24" upper_limit="15.60"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Analysis not specified for alternate strain.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Analysis was not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Yamagata Strain: SCR Difference (aTIV-1 - aQIV).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of aQIV vs. aTIV-1 for the alternate B strain was assessed using the difference in SCR (SCRaTIV–SCRaQIV) at Day 22. Superiority was declared if the upper limit of the two-sided 95% CI for the difference in SCRs (aTIV–aQIV) was &lt;0, for both B strains. The superiority comparison was based on the FAS Immunogenicity.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>-11.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.12</ci_lower_limit>
            <ci_upper_limit>-8.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>B/Victoria Strain: SCR Difference (aTIV-2 - aQIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of aQIV vs. aTIV-2 for the alternate B strain was assessed using the difference in SCR (SCRaTIV-SCRaQIV) at Day 22. Superiority was declared if the upper limit of the two-sided 95% CI for the difference in SCRs (aTIV-aQIV) was &lt;0, for both B strains. The superiority comparison was based on the FAS Immunogenicity.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>-10.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.54</ci_lower_limit>
            <ci_upper_limit>-8.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
        <time_frame>Day 1 through Day 7</time_frame>
        <population>The Solicited Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data (solicited AE data).</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
          <population>The Solicited Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data (solicited AE data).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="883"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="438"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Subjects With Unsolicited AEs</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
        <time_frame>Day 1 through Day 22</time_frame>
        <population>The Overall Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Subjects With Unsolicited AEs</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.</description>
          <population>The Overall Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="888"/>
                <count group_id="O2" value="444"/>
                <count group_id="O3" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)</title>
        <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.</description>
        <time_frame>Day 1 through Day 181</time_frame>
        <population>The Overall Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV</title>
            <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
          </group>
          <group group_id="O2">
            <title>aTIV-1</title>
            <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
          </group>
          <group group_id="O3">
            <title>aTIV-2</title>
            <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)</title>
          <description>Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.</description>
          <population>The Overall Safety Set consists of all subjects in the FAS who received at least one dose or partial dose of study vaccine and have provided any evaluable follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="888"/>
                <count group_id="O2" value="444"/>
                <count group_id="O3" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and unsolicited AEs: Day 1 through 181; Solicited AEs: Day 1 through 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>aQIV</title>
          <description>MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.</description>
        </group>
        <group group_id="E2">
          <title>aTIV-1</title>
          <description>Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.</description>
        </group>
        <group group_id="E3">
          <title>aTIV-2</title>
          <description>MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2): The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="461" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="215" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="888"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seqirus Clinical Trial Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>Phone: 1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

